Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

Medicine & Life Sciences

• N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine 100%
• Molecular Targeted Therapy 85%
• Cholangiocarcinoma 72%
• ErbB Receptors 60%
• Cell Line 26%
• Heterografts 16%
• Vascular Endothelial Growth Factor Receptor-2 11%
• Neoplasm Metastasis 11%
• Mutation 10%
• Growth 9%
• Vascular Endothelial Growth Factor A 7%
• Therapeutics 5%
• In Vitro Techniques 3%
• Neoplasms 2%